Olema Oncology
Salvador Corona has extensive experience in clinical data management, starting as a Clinical Data Manager at PAREXEL in 2000. Salvador progressed to roles such as Senior Clinical Data Manager at Vertex Pharmaceuticals, Principal Data Manager at Harvard Clinical Research Institute, and Director of Clinical Data Management at SQZ Biotechnologies and Olema Oncology. Salvador's career spans over two decades in the pharmaceutical and biotechnology industry, showcasing leadership and expertise in managing clinical trial data.
Salvador Corona studied Biology, General and obtained a Bachelor of Science degree from Stonehill College. In 2020, they obtained a certification in GCP for Clinical Trials with Investigational Drugs and Biologics from CITI Program, A Division of BRANY.
This person is not in any offices
Olema Oncology
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Their lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. They are supported in their mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies.